27 September 2021 - - Michael Amoroso has been named as US-based clinical stage biotechnology company Precision BioSciences, Inc's (NASDAQ: DTIL) president and chief executive officer and a member of the Precision BioSciences board of directors, in each case effective October 15, 2021, the company said.

Amoroso will succeed Matt Kane, Co-Founder, president and chief executive officer, who is expected to serve as an advisor to the company to help ensure a smooth transition.

Amoroso is a biotech CEO with significant operational experience leading organizations focused on cell and gene therapies.

He brings extensive experience leading teams across research, clinical development, regulatory and medical affairs, and commercial operations, with direct operational experience in the US and major world markets with a particular focus on oncology drugs, including CAR T cell therapies for hematologic malignancies.

Amoroso is currently president and chief executive officer of Abeona Therapeutics, Inc., a fully-integrated gene and cell therapy company.

Prior to this role, Amoroso served as Abeona's chief commercial officer and chief operating officer, responsible for overseeing the operational management of Abeona, including research and clinical development, regulatory, medical, commercial, corporate affairs, and business development.

Previously, Amoroso was the senior vice president and chief commercial officer at Kite Pharma, Inc.

He held various senior level executive positions at leading biopharmaceutical companies, including Eisai Inc., Celgene Corp., and began his biopharmaceutical career at Aventis (now Sanofi S.A.).

Amoroso earned his Executive M.B.A. in Management from the Stern School of Business, New York University, and his B.A. in Biological Sciences, summa cum laude, from Rider University.

Precision BioSciences is a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS genome editing platform.

ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind.

Using ARCUS, the company's pipeline consists of multiple "off-the-shelf" CAR T immunotherapy clinical candidates and several in vivo gene editing candidates to cure genetic and infectious diseases where no adequate treatments exist.